← Oncology Approval Tracker

FDA DECISION ·

Tafinlar + Mekinist

dabrafenib + trametinib · Novartis

Accelerated approvalNew or expanded indicationTumor-agnostic solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children aged one year or older with BRAF V600E-mutant unresectable or metastatic solid tumors after progression on previous therapy and with no satisfactory alternative. The action lowered the age threshold from six years. It excludes colorectal cancer under this indication.

LAMPGEN ANALYSIS

Why it matters

This supplement expanded the tumor-agnostic BRAF-directed regimen to younger children.

What research teams should watch

Record age and tumor histology and distinguish the tumor-agnostic criteria from the separate low-grade glioma label.

PRIMARY RECORDS

Sources